Semin Speech Lang 2020; 41(01): 032-044
DOI: 10.1055/s-0039-3400990
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Moving Toward Non-transcription based Discourse Analysis in Stable and Progressive Aphasia

Sarah Grace Hudspeth Dalton
1  Department of Speech Pathology and Audiology, Marquette University, Milwaukee, Wisconsin
,
H. Isabel Hubbard
2  Department of Communication Sciences and Disorders, University of Kentucky, Lexington, Kentucky
,
Jessica D. Richardson
3  Department of Speech and Hearing Sciences, University of New Mexico, Albuquerque, New Mexico
› Author Affiliations
Funding S.G.H.D. receives salary from Marquette University. She has no other disclosures.
H.I.H receives salary from the University of Kentucky. She has no other disclosures.
J.D.R. receives salary from the University of New Mexico and grant support through an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM109089. She also serves as Co-Chair of the Research Committee at the Triangle Aphasia Project.
Further Information

Publication History

Publication Date:
23 December 2019 (online)

Abstract

Measurement of communication ability at the discourse level holds promise for predicting how well persons with stable (e.g., stroke-induced), or progressive aphasia navigate everyday communicative interactions. However, barriers to the clinical utilization of discourse measures have persisted. Recent advancements in the standardization of elicitation protocols and the existence of large databases for development of normative references have begun to address some of these barriers. Still, time remains a consistently reported barrier by clinicians. Non-transcription based discourse measurement would reduce the time required for discourse analysis, making clinical utilization a reality. The purpose of this article is to present evidence regarding discourse measures (main concept analysis, core lexicon, and derived efficiency scores) that are well suited to non-transcription based analysis. Combined with previous research, our results suggest that these measures are sensitive to changes following stroke or neurodegenerative disease. Given the evidence, further research specifically assessing the reliability of these measures in clinical implementation is warranted.

Supplementary Material